



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(51) Int Cl.:
C12N 7/01 ^(2006.01) **C12N 7/04** ^(2006.01)
C12N 15/86 ^(2006.01) **A61K 35/768** ^(2015.01)

(48) Corrigendum issued on:
30.12.2020 Bulletin 2020/53

(86) International application number:
PCT/EP2014/073120

(45) Date of publication and mention
of the grant of the patent:
16.10.2019 Bulletin 2019/42

(87) International publication number:
WO 2015/063085 (07.05.2015 Gazette 2015/18)

(21) Application number: **14809770.2**

(22) Date of filing: **28.10.2014**

(54) **INFLUENZA VIRUS VECTOR FOR VIROTHERAPY**
INFLUENZA-VIRUS-VEKTOR FÜR VIRENTHERAPIE
VECTEUR À VIRUS INFLUENZA POUR VIROTHERAPIE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **28.10.2013 EP 13190511**

(43) Date of publication of application:
07.09.2016 Bulletin 2016/36

(73) Proprietor: **Blue Sky Vaccines GmbH**
1060 Vienna (AT)

(72) Inventor: **MUSTER, Thomas**
1180 Wien (AT)

(74) Representative: **Loidl, Manuela Bettina et al**
REDL Life Science Patent Attorneys
Donau-City-Straße 11
1220 Wien (AT)

(56) References cited:
EP-A1- 2 708 552 WO-A1-2011/014504
WO-A2-01/64860

- **C. L. EFFERSON ET AL: "Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene", JOURNAL OF VIROLOGY, vol. 77, no. 13, July 2003 (2003-07), pages 7411-7424, XP055172262, ISSN: 0022-538X, DOI: 10.1128/JVI.77.13.7411-7424.2003**
- **KITTEL CHRISTIAN ET AL: "Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 16, August 2005 (2005-08), pages 10672-10677, XP002414818, ISSN: 0022-538X, DOI: 10.1128/JVI.79.16.10672-10677.2005**
- **MUSTER T ET AL: "Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 110, no. 1, 20 May 2004 (2004-05-20), pages 15-21, XP008088723, ISSN: 0020-7136, DOI: 10.1002/IJC.20078**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **M. WOLSCHEK ET AL:** "Establishment of a Chimeric, Replication-Deficient Influenza A Virus Vector by Modulation of Splicing Efficiency", **JOURNAL OF VIROLOGY**, vol. 85, no. 5, 22 December 2010 (2010-12-22), pages 2469-2473, XP055046389, ISSN: 0022-538X, DOI: 10.1128/JVI.01650-10
- **BERGMANN MICHAEL ET AL:** "A genetically engineered influenza A virus with ras-dependent oncolytic properties", **CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US**, vol. 61, no. 22, 15 November 2001 (2001-11-15), pages 8188-8193, XP002470603, ISSN: 0008-5472 cited in the application

- **B. FERKO ET AL:** "Immunogenicity and Protection Efficacy of Replication-Deficient Influenza A Viruses with Altered NS1 Genes", **JOURNAL OF VIROLOGY**, vol. 78, no. 23, 12 November 2004 (2004-11-12), pages 13037-13045, XP055090958, ISSN: 0022-538X, DOI: 10.1128/JVI.78.23.13037-13045.2004

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification